Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients
NCT04410341 · Sadat City University · PHASE1/PHASE2 · withdrawn · last registry update 2025-07-14 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Institutional and funding constrains” | – | Registry record, Sadat City University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DPP4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-06-09Phase 3 first posted: Sun Yat-sen University, Group A (triple combination intensive therapy group) + Group B (standard therapy group) (NCT07635953)
- 2026-05-12Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Cobimetinib (NCT03337698)
- 2026-05-12Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Cobimetinib (NCT03337698)
- 2026-02-10Results posted on the registry: GRADE Study Group, Sulfonylurea (glimepiride) + DPP-4 inhibitor (sitagliptin) (NCT01794143)
- 2026-01-28Results posted on the registry: Mayo Clinic, Sitagliptin + Dapagliflozin (NCT06263673)
- 2025-12-18Also stopped (withdrawn): Eurofarma Laboratorios S.A., N0892 + Januvia® + Glifage XR® + Placebo (NCT06560333)
- 2025-08-03Results posted on the registry: Vanderbilt University Medical Center, Valsartan + LCZ696 (NCT03738878)
- 2025-08-03Also stopped (terminated): Vanderbilt University Medical Center, Valsartan + LCZ696 (NCT03738878)
- 2025-07-30Phase 3 first posted: Celltrion, Metformin + Alogliptin (NCT07093476)
- 2025-07-21Phase 3 first posted: Daewon Pharmaceutical Co., Ltd., DW1026C1 + DW1026C2 (NCT07076056)
- 2025-07-18Phase 3 first posted: Khyber Medical College, Peshawar, Trelagliptin 100 mg + Sitagliptin 100mg OD (NCT07073768)
- 2025-07-14Also stopped (withdrawn): Sadat City University, Vildagliptin 50 MG + Placebo (NCT04761861)
- 2025-06-24Phase 3 first posted: Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair, Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes + China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes (NCT07033585)
- 2025-04-30Phase 3 first posted: University of Lahore, Sitagliptin + Metformin + Empagliflozin + Metformin (NCT06952231)
- 2025-04-27Phase 3 first posted: Sun Yat-sen University, Group A (triple combination therapy group) + Group B (standard therapy group) (NCT06946628)
- 2025-01-13Phase 3 first posted: Azienda Policlinico Umberto I, Sitagliptin 100 mg + Placebo Tablets (NCT06770894)
- 2024-11-12Results posted on the registry: AstraZeneca, dapagliflozin and saxagliptin (NCT04445714)
- 2024-09-19Also stopped (withdrawn): George Medicines PTY Limited, GMRx-4 IR polypill - sitagliptin, dapagliflozin, metformin + Metformin (NCT05833958)
- 2024-08-19Phase 3 first posted: Eurofarma Laboratorios S.A., N0892 + Januvia® + Glifage XR® + Placebo (NCT06560333)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision